logo evento
Madrid
26/27 Noviembre 2026

Program

Thursday, 26 November
08:00 – 09:30
SPECIAL SESSION: Thoracic surgery
Chairs:
Dr. David Gómez Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
Dr. Unai Jiménez Hospital Univ. de Cruces, Barakaldo
08:00 – 08:15
RESECT & RTT (GECP)
Dr. Raúl Embún Hospital Univ. Miguel Servet, Zaragoza
08:15 – 08:30
Multidisciplinary treatment of thymic tumors
Dr. Carlos Martínez-Barenys Hospital Univ. Germans Trias i Pujol, Barcelona
08:30 – 08:45
The utility of synthetic data cohorts in surgical clinical studies of lung cancer
Dr. Gabriel Barceló Hospital Clínico San Carlos, Madrid
08:45 – 09:00
Sub-lobar resections after neoadjuvant treatment
Dr. Lucía Reyes Hospital Univ. Mútua Terrassa, Barcelona
09:00 – 09:15
Predictors of pathological response after neoadjuvant chemo-immunotherapy / Is surgery avoidable after neoadjuvant chemo-immunotherapy? VALID study (GECP)
Dr. Mariano Provencio Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
09:15 – 09:30
Discussion
08:00 – 09:30
SPECIAL SESSION: Translational Research (Newman meeting room)
Chairs:
TBC
08:00 – 08:15
Tumor Resistance after Neoadjuvant Chemoimmunotherapy: Insights from Spatial Transcriptomics Analysis
Dr. Marta Molina-Alejandre Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
08:15 – 08:30
Metagenomics in Lung Cancer: From Microbiome Profiling to Biomarkers and Therapeutic Opportunities
Dr. José Avendaño Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
08:30 – 08:45
cfDNA Methylome Deconvolution: New Opportunities for Liquid Biopsy in Lung Cancer
Prof. Tommy Kaplan The Hebrew University of Jerusalem (Israel)
08:45 – 09:00
Tertiary Lymphoid Structures and Disease Progression Following Perioperative Chemoimmunotherapy in NSCLC
Dr. Ángeles Gil-González Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
09:00 – 09:15
Beyond TMB and PD-L1: TCR Repertoire Metrics and Clonal Dynamics as Biomarkers in NSCLC
Dr. Cristina Martínez-Toledo Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
09:15 – 09:30
Discussion
09:30 – 09:45
Welcome
09:45 – 10:45
SESSION I: Future trends in lung cancer: beyond treatment
Chairs:
Dr. Mariano Provencio Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
Dr. Alberto Ruano Universidad de Santiago de Compostela, A Coruña
09:45 – 10:00
Radiomics in lung cancer: screening and delta radiomic
Dr. Leonor Cerdá Hospital Univ. y Politécnico La Fe, Valencia
10:00 – 10:15
AI-driven digital pathology: correlating histopathology with molecular profiles
Dr. Esther Conde Hospital Univ. 12 de Octubre, Madrid
10:15 – 10:30
The impact of exercise on lung cancer outcomes
Dr. Óscar Martínez The Ricky Rubio Foundation, Badalona
10:30 – 10:45
Discussion
10:45 – 11:15
Coffee break
11:15 – 12:25
SESSION II: Updates GECP studies and other projects
Chairs:
Dr. María Guirado Hospital General Univ. de Elche
Dr. María Ángeles Sala Hospital Univ. Basurto, Bilbao
11:15 – 11:25
GECP studies: early stages NSCLC (Nadim Adjuvant, Arian, Sabine, Caster, Merit, Athenea, Migrant)
Dr. Silvia Sequero Hospital Univ. Clínico San Cecilio, Granada
11:25 – 11:35
GECP studies: advanced stages NSCLC (CUBIK, Zone-Brain, Nivipi-Brain, Palace)
Dr. María Jové ICO, Hospital Duran i Reynals, L’Hospitalet de Llobregat, Barcelona
11:35 – 11:45
GECP studies: other thoracic tumors and pharmacogenomics projects (Dumas, Peers, Merlin, Pelícano, Real Nadim, Sienna)
Dr. Hugo Arasanz Hospital Univ. de Navarra
11:45 – 11:55
GECP registries (RTT, Atlas, Liquid Radon, Eliot, Oncogénero)
Dr. Karla Medina Hospital Univ. Ntra. Sra. de Candelaria, Santa Cruz de Tenerife
11:55 – 12:05
Consensus on the definition of complete resection of NSCLC
Dr. Vanessa Ospina Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
12:05 – 12:15
SLCG accreditation of excellence for thoracic tumor boards
Dr. Teresa Morán ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona
12:15 – 12:25
Discussion
12:25 – 13:25
SESSION III: Early stages: a changing field in lung cancer
Chairs:
Dr. Florentino Hernando-Trancho Hospital Clínico San Carlos, Madrid
Dr. Sergio Vázquez Hospital Univ. Lucus Augusti, Lugo
12:25 – 12:40
Neoadjuvant vs. perioperative treatment: patient selection criteria
Dr. Patrick Forde St. James’s Hospital, Dublin (Ireland)
12:40 – 12:55
Choosing between neoadjuvant and perioperative therapy: who benefits most?
Dr. Mariano Provencio Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
12:55 – 13:10
Present and future of targeted therapies in early stage
Dr. Rosario García Campelo Hospital Univ. de A Coruña
13:10 – 13:25
Discussion
13:25 – 14:55
Lunch
13:25 – 14:55
Lunch Satellite Symposium (J. Maritain meeting room)Sponsored by BeOne
14:55 – 16:10
SESSION IV: Locoregional lung cancer: current management and future directions
Chairs:
Dr. Alfredo Sánchez Hospital Provincial de Castellón
Dr. Javier Luna Hospital Univ. Fundación Jiménez Díaz, Madrid
14:55 – 15:10
State of the art in the management of locoregional disease
Dr. Anna Estival Hospital Univ. Insular de Gran Canaria, Las Palmas
15:10 – 15:25
The role of SBRT in locoregional disease
Dr. Suresh Senan Amsterdam University Medical Centers (Netherlands)
15:25 – 15:40
New strategies beyond the PACIFIC trial
Dr. Enric Carcereny ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona
15:40 – 15:55
Targeted therapies in unresectable NSCLC
Dr. Huang Yiqing National Cancer Centre Singapore
15:55 – 16:10
Discussion
16:10 – 16:25
Coffee break
16:25 – 17:40
SESSION V: Hopes and hypes of ctDNA
Chairs:
Dr. Eloísa Jantus Hospital General Univ. de Valencia
Dr. Alejandro Olivares Hospital Univ. de Salamanca
16:25 – 16:40
Approach to ctDNA techniques
Dr. Atocha Romero Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
16:40 – 16:55
The role of ctDNA in early detection
Dr. Roberto Serna Hospital Univ. Puerta de Hierro, Majadahonda, Madrid
16:55 – 17:10
ctDNA in advanced NSCLC
Dr. Manuel Cobo Hospital Regional Univ. de Málaga
17:10 – 17:25
ctDNA in targeted therapies
Dr. Patricia Iranzo Hospital Univ. Vall d’Hebron, Barcelona
17:25 – 17:40
Discussion
17:40 – 18:45
SESSION VI: Immunotherapy in advanced NSCLC
Chairs:
Dr. Juan Coves Hospital Son Llàtzer, Palma de Mallorca
Dr. Mónica Antoñanzas Hospital Clínico San Carlos, Madrid
17:40 – 17:55
Novel immunotherapy strategies: the emergence of bispecific antibodies
Dr. Óscar Juan-Vidal Hospital Univ. y Politécnico La Fe, Valencia
17:55 – 18:10
Predictive factors of response in advanced NSCLC
Dr. Carlos Aguado Hospital Clínico San Carlos, Madrid
Debate: the importance of administration timing in oncology
18:10 – 18:20
Pros
Dr. Enriqueta Felip Hospital Univ. Vall d’Hebron, Barcelona
18:20 – 18:30
Cons
Dr. Bartomeu Massutí Hospital General Univ. Dr. Balmis, Alicante
18:30 – 18:45
Discussion
18:45 – 19:15
Satellite Symposium (J. Maritain meeting room)Sponsored by Pierre Fabre
CPNM BRAF V600E: nuevas evidencias, integrando perspectivas